STRO

Rating neutralAI Memo

Sutro Biopharma

As of 2026-04-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Astellas collaboration milestone receipt • 2026-06-30

Expected move: +11%

Biggest risk

The bear case is that STRO remains an early-stage, low-coverage biotech with heavy dependence on one lead clinical readout, ongoing cash burn, and only partial de-risking from partner activity; if STRO-004 data are equivocal, the stock can re-rate sharply lower despite runway [#10-K-2026-03-23].

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The bull case is that STRO-004 shows tolerable early safety and enough activity to support best-in-class TF ADC positioning, while Astellas milestones and 2028 runway reduce immediate dilution pressure and allow multiple shots on goal through 2026 [#8-K-2026-03-23].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-15

Base target

$27

p=45%

Bull target

$38

p=25%

Bear target

$18

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

AACR 2026 pipeline visibility
2026 pipeline execution versus financing overhang
The bull case is that STRO-004 shows tolerable early safety and enough activity to support best-in-class TF ADC positioning, while Astellas milestones and 2028 runway reduce immediate dilution pressure and allow multiple shots on goal through 2026 [#8-K-2026-03-23].

BearKey bullets

Future capital needs remain significant despite runway extension
Low coverage and small-cap biotech liquidity can amplify downside on sparse news flow
Partnered milestones slip or prove less economically meaningful than expected

WatchKey bullets

Astellas collaboration milestone receipt

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $27 (p=45%)

Bull/Bear spread: +56% / -26%

Vs latest close: Bull +56% · Base +11% · Bear -26%

Scenario probabilities

Bull Target: $38 (p=25%)Base Target: $27 (p=45%)Bear Target: $18 (p=30%)

Commentary

Primary-source support is real, but the evidence still points to a monitoring-style thesis: deterministic priors are negative, forward value realization depends heavily on one mid-2026 clinical event, and the peer set is loose. The recent financing and Astellas progress help, yet conviction should stay restrained until STRO-004 human data arrive.

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

AACR 2026 pipeline visibility
2026 pipeline execution versus financing overhang

Scenarios

Bull Target (Scenario probability)

$38 / p=25% prob

Base Target (Scenario probability)

$27 / p=45% prob

Bear Target (Scenario probability)

$18 / p=30% prob

Price $24 as of 2026-06-02

Nearest Scenario: Base (∆ 11%)

Targets vs latest close: Bull +56% · Base +11% · Bear -26%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
Astellas collaboration milestone receipt
The partnered TROP2 dual-payload iADC has entered the clinic with patient dosing underway, and Sutro said the start triggered a $10 million milestone payment expected in Q2 2026; receipt would modestly reinforce external validation and liquidity, though not likely change the thesis alone [#8-K-2026-03-23].
Prob 70.00% • Move 10.00% • Priced-in 55.00%
EVENT2026-07-15
STRO-004 initial Phase 1 clinical data
Management said STRO-004 completed dosing across three cohorts and expects initial clinical data in mid-2026, including safety, PK exposure and potentially early activity; this is the clearest upside or downside driver because the program is the lead wholly owned clinical asset [#8-K-2026-03-23][#10-K-2026-03-23].
Prob 75.00% • Move 35.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

AACR 2026 pipeline visibility
2026-04-19
AACR presentations scheduled for April 19-21, 2026 give near-term visibility into STRO-004, STRO-006, STRO-227 and the partnered TROP2 iADC, but this looks more like scientific framing than a decisive value inflection absent clearly differentiated data [#8-K-2026-03-23].
Prob 80% • Move 6% • Priced-in 70%

Long-term Catalysts

Months to a year

2026 pipeline execution versus financing overhang
2026-12-31
Sutro said STRO-227 remains on track for a 2026 IND submission, STRO-006 is expected to enter clinical development in 2026, and cash plus the recent raise extended runway into at least Q2 2028, but the 10-K still frames capital needs as material and the March 2026 ATM termination removes one financing avenue, leaving execution quality and future capital access central to valuation [#8-K-2026-03-23][#10-K-2026-03-23].
Prob 60% • Move 22% • Priced-in 50%

Risks

Future capital needs remain significant despite runway extension
Low coverage and small-cap biotech liquidity can amplify downside on sparse news flow
Partnered milestones slip or prove less economically meaningful than expected
STRO-004 mid-2026 data disappoint on safety, PK or early efficacy

Peers

Symbol	Summary
DTIL	Loose peer rather than a direct ADC comp; useful mainly as a small-cap clinical biotech with binary data and financing sensitivity similar to STRO.
BMEA	Another loose small-cap biotech peer where valuation is dominated by clinical credibility, cash runway and readout timing rather than current revenue.
CSBR	Less mechanistically aligned, but still a micro/small-cap life sciences name that helps frame how thin liquidity and catalyst concentration can distort price reactions.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15

AI Stock Memo: STRO - Sutro Biopharma - RankAlpha